Wegovy for Weight Loss
Novo Nordisk's weekly weight loss shot. Patients in the main clinical trial lost about 15% of their body weight on average, and Wegovy is the only GLP-1 with FDA-approved cardiovascular benefit for people with obesity.
Reviewed by GlobalGLP1 editorial team • Last reviewed March 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Overview
Wegovy is a once-weekly injection from Novo Nordisk that helps you lose weight by reducing appetite and slowing how fast your stomach empties. The FDA approved it in June 2021 for adults whose weight is affecting their health (and in 2022 for adolescents 12 and older). It uses the same active ingredient as Ozempic (semaglutide), but at a higher dose specifically labeled for weight loss. In the main study (called STEP 1), people on the 2.4 mg dose lost about 14.9% of their body weight over 68 weeks. For a 200-pound person, that is roughly 30 pounds. In March 2026 the FDA approved a higher-dose version called Wegovy HD (7.2 mg) for people who may benefit from additional weight loss.
How Wegovy Works
Wegovy works by copying a hormone your body already makes called GLP-1. This hormone tells your brain you are full, slows down how fast food leaves your stomach, and helps control blood sugar after meals. You take it as a once-weekly shot (usually in the belly, thigh, or upper arm). Over time, most people eat less without feeling like they are fighting hunger all day.
FDA Approval
Wegovy
Chronic weight management
0.25 mg to 2.4 mg weekly injection (escalating dose)
Wegovy HD
Chronic weight management (higher dose)
7.2 mg weekly injection
How You Take It
The slow dose build-up is important. It gives your body time to adjust and helps reduce stomach side effects. Most people reach the full dose in about 4 to 5 months. Your doctor may slow things down if side effects bother you.
How Much Weight You Can Lose
In the main clinical trial, people on Wegovy 2.4 mg lost about 14.9% of their body weight over 68 weeks (roughly 16 months). About one in three lost 20% or more. The newer Wegovy HD dose (7.2 mg), approved in 2026, showed about 20% average weight loss in trials. For a 200-pound person, 15% is about 30 pounds.
Side Effects
Common Side Effects
- Nausea (about 44% of users in the STEP 1 trial; usually worst during dose increases and eases after a few weeks)
- Diarrhea (about 32% of users; usually mild and short-lived)
- Vomiting (about 25% of users; tends to drop off after the first month or two)
- Constipation (about 23% of users; staying hydrated and adding fiber usually helps)
- Abdominal pain (about 20% of users; usually mild)
- Headache (about 14% of users)
- Fatigue (about 11% of users; often improves as your body adjusts)
- Injection site reactions (uncommon; mild redness or itching near the shot)
Rare but Serious
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning, observed in rodents)
- Hypoglycemia (when combined with insulin or sulfonylureas)
- Kidney injury (due to dehydration from GI effects)
- Allergic reactions
Managing side effects: Most stomach-related side effects show up during the first few weeks and during dose increases, then ease as your body adjusts. The slow dose build-up exists for this reason. Eating smaller meals, staying hydrated, and avoiding fatty or fried foods help a lot. If nausea is bad enough that you cannot keep food down, contact your provider. They can slow the dose escalation or pause it for a cycle.
Wegovy Cost & Savings (2026)
Savings programs: Wegovy Savings Card: commercially insured patients can pay as little as $0/month if their plan covers Wegovy, or save up to $225/month if it does not. NovoCare Pharmacy: cash-paying patients can buy Wegovy direct from Novo Nordisk for a flat $499/month for all doses. Medicaid and Medicare patients are not eligible for the savings card.
Who Should Not Take Wegovy
- Personal or family history of a type of thyroid cancer called medullary thyroid carcinoma (MTC)
- A rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Allergy to semaglutide or any ingredient in the medication
- Pregnancy or planning to become pregnant (stop at least 2 months before conception)
- History of inflamed pancreas (pancreatitis) — use with caution
Heart Health
The SELECT trial followed over 17,600 adults with obesity and heart disease (but not diabetes) for about 3 years. People on Wegovy had 20% fewer major heart events compared to people on placebo. This is the only weight loss medication with proven heart benefits in people who do not have diabetes.
What this means for you: If you have obesity and heart disease, Wegovy is one of the only treatments shown to reduce your risk of heart attack and stroke on top of helping you lose weight. This is also why some insurance plans and Medicare have started covering it.
What to Expect, Month by Month
Most patients notice decreased hunger and food cravings. Portion sizes naturally decrease.
Measurable weight loss begins as doses escalate. Average 2-4% body weight lost during escalation phase.
Maintenance dose reached. Consistent weight loss of 1-2 lbs per week. Most GI side effects have resolved.
Average 10-15% body weight lost. Blood pressure, cholesterol, and blood sugar improvements measurable.
Weight loss plateau at 15-17% average. Metabolic health markers stabilized. Maintenance phase begins.
Other Medications to Watch
Can cause dangerously low blood sugar when combined. Your doctor will likely reduce your insulin dose by 20 to 50% when starting semaglutide.
Because semaglutide slows digestion, pills you take by mouth may absorb differently. Take other oral medications at least 1 hour before your semaglutide injection day meals.
Slower digestion can change how warfarin absorbs. Your doctor should check your clotting levels (INR) more often when starting or changing your semaglutide dose.
Slower digestion could slightly reduce how well birth control pills absorb. Consider backup contraception during the first few months or switch to a non-oral method (patch, ring, IUD).
Special Situations
Do not use during pregnancy. Stop semaglutide at least 2 months before trying to conceive because it stays in your system for weeks. Animal studies showed harm to the fetus.
No dose change needed for mild or moderate kidney issues. If you have severe kidney disease, use with caution because the nausea and vomiting can cause dehydration, which makes kidney problems worse.
No dose change needed. Semaglutide is not processed by the liver.
No dose change needed. Clinical trials included people up to age 75. Older adults should watch for dehydration since stomach side effects can cause extra fluid loss.
Wegovy is FDA-approved for teens 12 and older with obesity. In the STEP TEENS trial, adolescents saw a 16.1% reduction in BMI. The dosing schedule is the same as for adults.
What Happens If You Stop
In the STEP 1 follow-up, people who stopped semaglutide after 68 weeks regained about two-thirds of the weight they had lost over the following year. Improvements in blood sugar, blood pressure, and cholesterol also partially reversed.
How to make stopping easier: Tapering your dose gradually (instead of stopping suddenly), building exercise habits while on the medication, working with a dietitian, and transitioning to a lower-cost maintenance plan can all reduce regain. Some doctors recommend staying on a low maintenance dose long-term.
Wegovy FAQs
Wegovy and Ozempic are the same drug (semaglutide) made by the same company, just sold under different names for different uses. Ozempic is approved for type 2 diabetes. Wegovy is approved for weight loss and uses a higher maximum dose (2.4 mg versus 2 mg). Your doctor will prescribe whichever one matches your situation, and your insurance is likely to cover only the one that fits your diagnosis.
The list price at retail pharmacies is about $1,349 per month. But Novo Nordisk sells Wegovy directly to cash-paying patients through NovoCare Pharmacy for a flat $499 per month at any dose. That is often the cheapest legitimate way to pay cash. You can sign up at novocare.com and get it shipped to your home or picked up at a local pharmacy.
In the main clinical trial (STEP 1), people on the 2.4 mg dose lost about 14.9% of their body weight over 68 weeks. About one in three participants lost 20% or more. The new Wegovy HD (7.2 mg) dose approved in 2026 showed even higher weight loss in trials, averaging around 20%. Results vary a lot from person to person depending on diet, exercise, and how your body responds.
It depends on your plan. Many large commercial insurance plans now cover Wegovy, but they usually require prior authorization. That means your doctor has to send paperwork showing you qualify (typically a BMI of 30 or higher, or 27+ with another weight-related health condition like high blood pressure or sleep apnea). Medicare does not cover GLP-1s for weight loss alone, but it does cover Wegovy specifically for people with obesity and cardiovascular disease (a new coverage added after the SELECT trial). Medicaid coverage varies by state. Use the clinic directory below to find providers that accept your insurance.
Yes, for people with obesity and existing heart disease. In the SELECT trial (2023), Wegovy reduced major heart events (heart attack, stroke, and cardiovascular death) by 20% compared to placebo in adults with overweight or obesity and existing cardiovascular disease. This is the only GLP-1 with FDA-approved cardiovascular benefit in people without diabetes. It is a major reason some insurance plans and Medicare have expanded Wegovy coverage.
You need a prescription from a licensed doctor or nurse practitioner. You can get one in person or through a telehealth clinic, and many telehealth providers offer same-week video appointments. Use the directory below to compare clinics in your state that prescribe Wegovy, including their prices, telehealth options, and insurance accepted.
The most common side effects are stomach-related: nausea, diarrhea, vomiting, constipation, and stomach pain. They usually show up when you first start or move up to a higher dose, and most people find they get better after a few weeks. Rare but more serious risks include inflammation of the pancreas, gallbladder problems, and a warning about thyroid tumors (seen in animal studies, not confirmed in humans). Always tell your doctor about your full medical history before starting.
Find Clinics Offering Wegovy
Compare Wegovy providers by pricing, telehealth availability, and patient ratings.
Search Wegovy Clinics →Related Wegovy resources
Find Wegovy Clinics by State
Ready to start Wegovy?
Search our directory of 3,323 GLP-1 clinics. Filter by medication, insurance, and telehealth availability.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.